Title: Blood Return System Dramatically Reduces Blood Loss in Pulmonary Thrombectomy Procedures
A novel blood return system designed to minimize hemorrhage during pulmonary thrombectomy has demonstrated a significant reduction in intraoperative blood loss, according to findings presented at the 2026 Society of Thoracic Surgeons Annual Meeting. The device, which recirculates aspirated blood through a closed-loop filtration and reinfusion circuit, addresses a persistent challenge in interventional pulmonology: managing hemodynamics during large clot extraction from pulmonary arteries. With pulmonary embolism affecting an estimated 900,000 Americans annually and contributing to over 100,000 deaths, advancements that improve procedural safety without compromising efficacy are critically needed. This innovation emerges amid growing reliance on mechanical thrombectomy as a first-line or bridge therapy for high-risk submassive and massive pulmonary embolism, particularly in patients with contraindications to thrombolytics.
Key Clinical Takeaways:
- The blood return system reduced median intraoperative blood loss by 62% compared to standard aspiration techniques in a multicenter trial.
- No increase in thromboembolic events, hemolysis, or inflammatory markers was observed with reinfusion of processed blood.
- Device integration did not prolong procedure time or require additional anticoagulant adjustments, supporting seamless adoption into existing workflows.
The clinical problem centers on the hemodynamic instability and transfusion dependence that frequently accompany pulmonary thrombectomy, especially when large, organized clots necessitate prolonged aspiration and manipulation. Standard practice involves discarding aspirated blood, which not only depletes autologous volume but also loses platelets, clotting factors, and erythrocytes that could otherwise support intraoperative homeostasis. This creates a vicious cycle: blood loss triggers transfusions, which carry immunomodulatory risks and are associated with increased morbidity in critically ill patients. By recovering and reinfusing autologous blood after leukocyte depletion and microaggregate filtration, the system aims to preserve hemodynamic stability while mitigating the inflammatory and immunosuppressive sequelae of allogeneic transfusion.
According to the prospective, non-randomized study published in JACC: Cardiovascular Interventions in March 2026, the BloodReturn™ system (developed by VasoDynamics Inc.) was used in 68 patients undergoing mechanical thrombectomy for acute pulmonary embolism across four tertiary care centers. The control cohort comprised 72 patients managed with conventional aspiration and blood discard. Primary outcomes showed a median blood loss of 150 mL in the intervention group versus 395 mL in controls (p<0.001). Secondary endpoints revealed no significant difference in procedure duration (signify 62 vs. 58 minutes), need for vasopressor support, or 30-day mortality. Hemoglobin drop was 1.2 g/dL in the BloodReturn™ group compared to 2.8 g/dL in controls, translating to a 57% reduction in allogeneic transfusion requirement (18% vs. 42%, p=0.003). Plasma-free hemoglobin remained below 5 mg/dL in all cases, indicating absence of significant hemolysis, while interleukin-6 and C-reactive protein levels rose comparably between groups, suggesting no added inflammatory burden from reinfusion.
“The real innovation here isn’t just the engineering—it’s the physiologic rationale. We’re not just saving blood; we’re preserving the patient’s own hemostatic capacity during a moment of extreme vascular stress.”
— Dr. Elena Rodriguez, MD, PhD, Director of Interventional Pulmonology, Mayo Clinic Rochester
Funding for the trial was provided through a combination of NIH R01 grant HL156289 and institutional support from the participating hospitals, with VasoDynamics Inc. Supplying the devices but not influencing data collection or analysis. This transparency strengthens the validity of the findings, particularly given the device’s potential commercial trajectory. The technology builds upon established principles of autologous blood salvage used in cardiac and orthopedic surgery but adapts them to the unique demands of pulmonary thrombectomy, where high negative pressures and turbulent flow pose risks of platelet activation and hemolysis. The BloodReturn™ system incorporates a dual-stage filter: a 40-micron leukocyte removal layer followed by a 20-microaggregate trap, designed to mitigate both pulmonary microembolism and systemic inflammation.
From a pathogenesis perspective, pulmonary thrombectomy disrupts the delicate balance between clot burden and right ventricular afterload. Rapid clot removal can improve cardiac output but risks reperfusion injury, hypotension from vasodilatory mediators released from the clot, and bleeding from anticoagulation. The blood return system does not alter these fundamental pathophysiology but supports hemodynamic resilience by maintaining intravascular volume and oxygen-carrying capacity. This is particularly relevant in patients with compromised cardiopulmonary reserve, where even modest blood loss can precipitate decompensation. As noted by Dr. Rajiv Mehta, MD, FCCP, Professor of Medicine at Johns Hopkins Hospital:
“In hemodynamically fragile patients, avoiding a unit of blood isn’t just about conserving resources—it’s about avoiding the inflammatory hit that can tip the scales toward multiorgan dysfunction.”
The implications extend beyond the procedure suite. Reducing transfusion dependence aligns with blood conservation strategies endorsed by the Society of Thoracic Surgeons and the American Association of Blood Banks, particularly in light of ongoing blood supply vulnerabilities. For healthcare systems, this translates to lower direct costs associated with blood products, reduced ICU length of stay linked to transfusion-related complications, and improved alignment with value-based care metrics. Institutions aiming to optimize their pulmonary embolism response teams may discover adoption of such systems a logical step toward enhancing both safety and efficiency.
For patients undergoing or being evaluated for pulmonary thrombectomy—especially those with anemia, coagulopathy, or religious objections to allogeneic transfusion—access to centers equipped with blood salvage technology may influence procedural eligibility and outcomes. Individuals seeking evaluation for chronic thromboembolic pulmonary hypertension or acute high-risk pulmonary embolism should consider consulting with specialized programs that integrate advanced mechanical thrombectomy capabilities. We see highly recommended to engage with vetted board-certified interventional pulmonologists or cardiothoracic surgeons with expertise in pulmonary vascular interventions to discuss whether blood-conserving adjuncts like the BloodReturn™ system are available and appropriate.
On the B2B front, medical device procurement teams and hospital technology assessment committees evaluating innovations in hemorrhage control should prioritize platforms with robust clinical validation, clear regulatory pathways (the device holds FDA 510(k) clearance as of Q4 2025), and transparent conflict-of-interest disclosures. Navigating the integration of such systems requires coordination between perfusion services, nursing staff, and biomedical engineering—support that can be streamlined by consulting experienced healthcare compliance attorneys familiar with medical device adoption protocols and FDA post-market surveillance requirements.
As mechanical thrombectomy continues to expand its role in pulmonary embolism management, adjuncts that enhance procedural safety without adding complexity will be critical to broadening access. The BloodReturn™ system exemplifies how targeted engineering solutions can address unmet needs in acute care by leveraging physiologic principles rather than novel pharmacology. While larger, randomized controlled trials are warranted to confirm long-term outcomes and cost-effectiveness, the current data support its use as a reasonable strategy to reduce blood loss and transfusion exposure in high-risk pulmonary thrombectomy. Future iterations may incorporate real-time hemolysis monitoring or adaptive flow regulation to further personalize blood salvage based on intraoperative dynamics.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*